Authors: Roisin Conneely
Pharmaceutical policy announcements, promising drug trial data and more: check out our round-up of the biggest news from the neuroscience and neurology industry this week.
Our pick of the headlines this week:
Bellicum Pharmaceuticals forced to halt drug trials after three cases of brain damage reported
Positive results from Phase III eslicarbazepine acetate epilepsy trial
Pfizer confirms cull of neuroscience programs
Sunovion announce Phase III Parkinson’s trial results for apomorphine
Sage Therapeutics present findings from latest investigation into insomnia drug